drug studies for community acquired pneumonia 2009
Post on 24-Apr-2015
1.155 Views
Preview:
DESCRIPTION
TRANSCRIPT
Drug Study
Generic
Name
Brand
Name
Classifica
tion
Mechanism
of Action
Indicatio
n
Contraindic
ation
Side
Effects
How
Suppli
ed
Dosage
/
Freque
ncy
Nursing
Intervention
Omepraz
ole
Omepr
on
Proton
pump
inhibitor
Thought to
be a gastric
pump
inhibitor in
that it blocks
the final
step of acid
production
inhibiting
the H+
an/K+
ATPase
system at
Short
term
treatme
nt of
active
duodena
l ulcer.
Short
term (4-
8
weeeks)
treatme
nt of
Lactation.
Use as
maintenanc
e therapy
for
duodenal
ulcer
disease.
OTC use in
those who
have
trouble of
pain
Headac
he,
abdomi
nal
pain,
diarrhe
a, N&V,
URTI,
dizzines
s, rash.
IV
infusio
n
40mg
Once a
day
1.Consider
dosage
adjustment in
those with
impaired hepatic
function
especially when
used for
maintaining
clients with
erosive
esophagitis.
2.List reason for
123
the
secretory
surface of
the gastric
parietal cell.
Both basal
and
stimulated
acid
secretions
are
inhibited.
Serum
gastrin
levels are
increased
during the
first 1 to 2
weeks of
therapy and
erosive
esophagi
tis
diagnose
d by
endosco
py.
Maintain
healing
of
erosive
esophagi
tis.
Treatme
nt of
heartbur
n and
other
sympto
ms
swallowing
food, are
vomiting
blood, or
excreting
bloody or
black
stools.
therapy, triggers,
frequency,
characteristics of
S&S, other agents
trialed.
3.Record
abdominal
assessment,
radiographic/end
oscopic findings,
and H. pylori
result.
4.Administer one
hr before giving
meal.
5. Report any
changes in
urinary
elimination, pain,
discomfort, or
124
are
maintained
at such
levels during
the course
of therapy.
(Spratto
et.al.:2008:1
159)
associat
ed with
GERD.
persistent
diarrhea.
6. Avoid activities
that require
mental alertness
until drug effects
realized; may
cause dizziness.
7. For short term
use only, drug
inhibits total
gastric acid
secretion. Side
effects of
prolonged
therapy and
suppression of
acid secretion
alter bacterial
colonization and
125
lead to
hypoclorhydria
and
hypergastrenemi
a which may
cause an increase
risk for gastric
tumors.
Drug Study
Generic
Name
Bran
d
Nam
e
Classifica
tion
Mechanism
of Action
Indication Contraindic
ation
Side
Effects
How
Suppli
ed
Dosage
/
Freque
ncy
Nursing
Intervention
Piperacill
in
sodium
and
Zosy
n,
Pept
az
Antibiotic
,
Penicillin
A
combination
of
Piperacillin
(1)Appendi
citis
complicate
d by
Hypersensit
ivity to
penicillins,
cephalospor
Diarrhea,
constipat
ion, N&V,
dyspepsi
IV
infusio
n
4.5 gm
IV q 8
hours
1.For IV
administration
or infusion,
reconstitute
126
Tazobact
am
sodium
sodium and
Tazobactam
sodium, a
beta-
lactamase
inhibitor.
Tazobactam
inhibits
beta-
lactamases,
thus
ensuring
activity of
piperacillin
against
beta-
lactamase-
producing
microorganis
ms. Thus
rupture or
abscess
and
peritonitis
caused by
piperacillin
-resistant,
beta-
lactamase
producing
strains of
Escherichi
a coli,
Bacteroide
s fragillis.
(2)Commu
nity
Acquired
Pneumonia
of
ins, or beta-
lactamase
inhibitors.
a,
headach
e, rash,
rhinitis,
dyspnea,
abdomin
al pain.
the powder for
injection with 5
ml suitable
diluent/gram
piperacillin. IV
diluents that
can be used
include 0.9%
NaCl, sterile
water for
injection,
dextran 6% in
saline,D5W,KCl
40mEq,
bacteriostatic
saline/paraben
s,
bacteriostatic
water/parabens
, bacteriostatic
127
Tazobactam
broadens
the
antibiotic
spectrum or
piperacillin
to those
bacteria
normally
resistant to
it. (Spratto
et.al.:2008:1
269)
moderate
severity
caused by
piperacillin
-resistant,
beta-
lactamase
producing
strains of
Haemophil
us
influenzae.
(3)Moderat
e to severe
nosocomia
l
pneumonia
caused by
piperacillin
-resistant,
saline/benzyl
alcohol,bacteri
ostatic
water/benzyl
alcohol.
2.Note reasons
for therapy,
type, location,
characteristics
of S&S.
3. List any
sensitivity to
penicillins,
cephalosporins,
beta-lactamase
inhibitors, or
other allergens.
4. List drug
prescribed to
ensure none
128
beta-
lactamase
producing
strains of
Acinetobac
ter
baumanii.
(4)
Infections
caused by
piperacillin
-
susceptible
organisms
for which
piperacillin
is effective
may also
be treated
with this
interact
unfavorably.
Use of heparin
and oral
anticoagulants
may require
dosage
adjustments.
5. Monitor C&S,
lytes,
urinalysis,
hematologic,
coagulation
profile, renal,
LFTs; reduce
dosage with
renal
impairment.
6. Inform
family to report
129
combinatio
n.
any pain at
injection site,
fever/chills,
rash, diarrhea,
GI upset, lack
of response or
worsening of
condition.
Drug Study
Generic
Name
Bran
d
Nam
e
Classificat
ion
Mechanis
m of
Action
Indication Contraindica
tion
Side
Effects
How
Suppli
ed
Dosage/
Frequen
cy
Nursing
Intervention
clopidog
rel
winto
p
Anti-
platelet
drug
Inhibits
platelet
aggregati
Reduction
of MI,
stroke and
Lactation,
active
pathological
Appenda
ge
disorder
Tablet
s 75
mg
Clopidog
ral 75
mg i tab,
>Do not cofuse
with
antidepreesant
130
on by
inhibiting
binding of
adenosin
e
diphosph
ate (ADP)
to its
platelet
receptor
and
susbsequ
ent ADP
meditativ
e
activation
of
glycoprot
ein
GPII/IIa
ucercular
death in
patients
with
atheroscler
osis
documente
d by recent
stroke, MI
or
established
peripheral
arterial
disease
bleeding
such us
peptic ulcer
or
intracranial
hemorrhage
s,
headach
e, chest
pain, flu-
like
sympto
ms
PO,OD > Document
otheros dehoric
event or
established
peripheral
arterial disease
requiring
therapy.
> Asses for
active bleeding
as with ulcers or
intracranial
bleeding.
> list all drugs
prescribed/cons
umed esp. OTC.
> Consider 5
rights in giving
meds.
> Explain the
131
complex.
Effect on
receptors
is
irreversib
le thus
platelets
are
affected
for
remainde
r of their
lifespan.
(MIMS.co
m)
purpose of the
medication.
> obtain
baseline V/S.
> Document the
procedure.
132
Drug Study
Generic
Name
Brand
Name
Classificat
ion
Mechanis
m of
Action
Indicatio
n
Contraindica
tion
Side Effects How
Supplied
Dosage/
Frequen
cy
Nursing
Interventio
n
Acytylcyst
ien
Flulmu
cil
sachet
Mucolytic
s
Decrease
the
productio
n of
Acute
and
chronic
respirat
Contraindica
ted to
patients
having
Urticaria
bronchospa
sm, nausea,
vomiting.
100
mg
/200mg
sachet
200 mg
1 sachet
+ socc
h20
asses drug
expiration
date
>asses for
133
mucus at
respirator
y tracts
by
stimulatin
g the
productio
n of
glutathia
nce thus
decreasin
g the
viscosity
of
secretion
s.
ory tract
affection
s with
abundan
t mucus
secretio
ns.
asthma.
Patients with
history of
peptic ulcer.
Inhalatio
n
100mg/
ml
Syrup
100mg/5
ml x 150
ml
NGT bid drug
tolerance
characteri
zed
>obtain
baseline
v/s
>take the
drug with
meals
>advice
increase
fluid
intake
>consider
patients
safety
>evaluate
effectiven
ess of
134
drug
>chart
procedure
Drug Study
Generic
Name
Brand
Name
Classificat
ion
Mechanis
m of
Action
Indication Contraindica
tion
Side
Effects
How
Suppli
ed
Dosage/
Frequen
cy
Nursing
Interventio
n
Simvasta
tin
Vidast
at
Dyslipide
mic Agent
Reductio
n of low
density
lipprotien
In CHD:
Reduce risk of
death and non
fatal MI.
Active liver
disease or
unexplained
persistent
Constipat
ion
dyspepsi
a
Tablet
10
mg,20
mg, 30
Vidastat
40g I
tab NGT
Asses drug
expiration
date
>consider
135
cholester
ol in that
following
inhibition
of the
HWG-
COA
reductas
e
activity,
the LDL
receptor
activity
on the
liver is
increase
d and
this
leads to
increase
Reduce risk of
strike and
transient
ischemic
attacks. In
hypelipidemia:
an adjuct to
the diet to
reduce
elevated total-
c, LDL-C ,
apolipoprotien
B and TG in
patients with
primary hyper
choles
terolemia,
hanozygous
familial
hyrecholestero
elevations of
serum trans
aminoses
parphyria,
pregnancy
lactation
flatulence mg,40
mg
OD q8hr the 5 rights
of drug
administrati
on.
>obtain
baseline
data
>dissolve
solution
thoroughly
>
encourage
high fiber
diet, fluid.
> inform
patient
about the
mechanism
of drugs
>chart the
136
d
removal
of LDD
cholester
ol.
(KIMS.co
m)
gous or mixed
hyperlipidemia
.
(MIMS.co
procedure
>evaluate
effectivene
ss of drugs.
Drug Study
Generic
Name
Brand
Name
Classification Mechanis
m of
Action
Indication Contraindica
tion
Side
Effects
How
Supplied
Dosage/
Frequen
cy
Nursing
Interventio
n
Midozal
am
Dormic
um
Benzodiazepi
ness sedative
hyponotics
Inhibits
sympath
etic
Disturban
ces of
sleep
Premature
infants
myasthenia
Insomni
a in
psychosi
Ampule
5mg/1ml
5mg/
IVTT 2.8
mg OD
1. Assess
level of
sedation
137
nervous
system
activatio
n and
initiates
sedation
hyponoti
cs
rhythm,
insomnia
esp.difficu
lty in
falling
asllep
either
initially or
after
prematur
e
awakenin
g.
Sedation
in premed
before
surgical
or
diagnostic
procedure
gravis s severe
depressi
on
5ml,15
mg/3ml
Film
coated
tablet 15
mg
and level
of
consciousn
ess
through
out and for
2-6 hour
following
administrat
ion
2. Monitor
blood
pressure,
pulse and
respiration
continuous
ly during
administrat
ion
3.
138
s,
induction
and
maintena
nce of
anesthesi
a.
(MIMS.co
m)
Administer
IM doses
deep into
muscle
4. In form
the patient
that this
medication
will
decrease
mental
recall of
the
procedure
5. Instruct
patient to
inform
health care
profession
al prior to
139
administrat
ion if
pregnancy
is
suspected
Drug Study
Generic
Name
Brand
Name
Classificatio
n
Mechanism
of Action
Indicati
on
Contraindicati
on
Side
Effects
How
Suppli
ed
Dosage/
Frequen
cy
Nursing
Interventio
n
Ciprofloxa
cin
ciprob
ay
fluroquinolo
ne
Has a rigid
action in
the
For
acute
uncomp
Contraindicate
d to patients
having
Nausea,
diarrhea
,
Tablet
250
mg,
Ciproba
y 500 g
1 ½ tab
>asses
drug
expiration
140
ploriferatio
n phase of
a
bacterium,
a
segmental
twisting
and
untwisting
of
chromoso
mes take
place.
(MIMS.com
)
li-cated
urinary
tract
infectio
ns
hypersensitivit
y to
ciprofloxacin
or other
quilone
chemotherape
utic
vomiting
,
dyspepsi
a,
abdomin
al pain,
flatulenc
e,
dizzines
s
500
mg
Infusio
n 100
mg/30
ml
200
mg/20
ml
Film
coated
tablet
500
mg
PO bid date
>asses for
drug
tolerance
characteriz
ed
>obtain
baseline
v/s
>instruct
the
patients to
remain in a
stable
position for
2-3 hrs.
>advice
increase
fluid intake
>consider
141
patients
safety
>evaluate
effectivene
ss of drug
>chart
procedure
Drug Study
Generic
Name
Brand
Name
Classificati
on
Mechanism
of Action
Indication Contraindicat
ion
Side
Effects
How
Suppli
ed
Dosage/
Frequen
cy
Nursing
Interventio
n
rebamipi
de
Mucust
a
ANTACIDS Rebamipid
e is a
For acute
gastritis
Lactation. Rash,
pruritus,
Tablet
100
Mucosta
1 tab
1. Chedk
renal
142
mucosal
protective
agent and
is
postulated
to increase
gastric
blood flow,
prostaglan
din
biosynthes
is and
decrease
free
oxygen
radicals.
and
exacerbati
on of
chronic
gastritis,
gastric
ulcers
constipati
on,
diarrhoea,
nausea.
mg OD TID studies to
check
renal
function is
normal
2. Check
the pattern
of bowel
elimination
.
3. Record
the gastric
pain being
experience
d.
4. report
for coffee
ground
stools
143
5. if the
patient is
pregnant
has edema
or
hypertensi
ve, use low
sodium
antacids
Drug Study
Generic
Name
Bran
d
Nam
e
Classificati
on
Mechanism
of Action
Indicatio
n
Contraindica
tion
Side
Effects
How
Supplied
Dosage/
Frequen
cy
Nursing
Interventio
n
144
predniso
ne
pred corticoster
oids
The anti-
inflammato
ry effect is
due to
inhibition
of
prostaglan
din
synthesis,
the drug
also
inhibits
accumulati
on of
machropha
ges and
leukocytes
at sites of
inflammati
on and
Allergis
and
edemato
us
respirato
ry and
neoplast
ic
diseases
Gastric &
duodenal
ulcers,
systemic
fungal &
certain viral
infections,
glaucoma,
psychoses or
severe
psychoneuro
ses; live
vaccines;
hypersensitiv
ity to
glucocorticoi
ds.
Insomia,
nosia and
vomiting,
GI upset,
fatique,
dizziness,
muscle
weakness,
increased
hunger/thi
rst, joint
pain,
decreased
diabetic
control.
tablets:1
mg, 5mg,
10mg, 20
mg, 50
mg
Oral
solution:
5mg/5ml;
syrup
5mg/5ml;
20 mg 1
tab NGT
BID
1. note
reasons for
therapy,
type,
onset,
characteris
tics of
signs and
symptoms,
clinical
presentatio
n
2. monitor
CBC, ESR,
electrolyte
s, BP,
blood
sugar,
weights
and mental
145
inhibits
phagocytos
is and
lysosomal
enzyme
release.
status.
3. with
COPD
provide
rescue
doses and
instruct
client how
and when
to use.
4. with
chronic
pain,
titrate dose
to assess
for relief
146
Drug Study
Generic
Name
Brand
Name
Classificati
on
Mechanism
of Action
Indicati
on
Contraindica
tion
Side Effects How
Suppli
ed
Dosage/
Frequen
cy
Nursing
Intervention
Ivabradi
ne HCl
corala
n
Antiangina
Ivabradine
Ivabradine
is a pure
Chronic
angina
Resting
heart rate
Luminous
phenomena
film-
coated
5 mg 1
tab NGT
1. Assess
the client for
147
heart rate-
lowering
agent,
acting by
selective
and specific
inhibition of
the cardiac
pacemaker /
current that
controls the
spontaneou
s diastolic
depolarisati
on in the
sinus node
and
regulates
heart rate.
The cardiac
pectotis <60 bpm
prior to
treatment,
cardiogenic
shock, acute
MI, severe
hypotension
(<90/50
mmHg),
severe
hepatic
insufficiency,
sick sinus
syndrome,
SA block,
severe heart
failure,
pacemaker-
dependent
patient,
(phosphene
s), blurred
vision,
bradycardia
, 1st
degree AV
block,
ventricular
extrasystol
es,
headache,
dizziness.
tablet
5 mg,
7.5 mg
OD gastrointesti
nal
upset and
peripheral
edema.
2. Assess
pain and
limitation of
movement ;
note type,
location &
intensity
prior to & at
the peak
following
administrati
on.
3. Monitor
vital signs
148
effects are
specific to
the sinus
node with
no effect on
intra-atrial,
atrioventric
ular or
intraventric
ular
conduction
times, nor
on
myocardial
contractility
or
ventricular
repolarisati
on.
unstable
angina, 3rd
degree AV-
block.
Concomitant
potent
CYP3A4
inhibitors.
Pregnancy &
lactation.
and check
for
peripheral
edema.
d. Don’t
breastfeed
while taking
this drug.
4.
Discontinue
drug and
notify
physician if
signs and
symptoms of
hypersensiti
vity occur.
5. Caution
the patient
to avoid
149
concurrent
use of
alcohol with
this
medication.
Drug Study
Generic
Name
Brand
Name
Classificati
on
Mechanis
m of
Action
Indication Contraindicat
ion
Side
Effects
How
Supplie
d
Dosage/
Frequen
cy
Nursing
Interventi
on
Co
amoxicl
av
Agcom
en
Amoxicillin
and
enzyme
Prevents
the
plorefirati
Bacterial
infections
caused by
Pregnancy &
lactation.
Elderly &
Diarrhea,
hepatitis
&
tablet
625
625 mg
1 tab
NGT q 8
a. Assess
for allergy
to
150
inhibitor on of of
infecting
bacteria
by
inhibitng
synthesis
of
bacterial
capcule.
(mims.co
m)
amoxicillin-
resistant β-
lactamase
producing
strains.Thes
e include
actinomycos
is, biliary
tract
infections,
bronchitis,
endocarditis
,
gastroenteri
tis, typhoid
& para
typhoid
fever & UTI.
neonates.
Severe renal
impairment.
cholestati
c
jaundice.
Erythema
multiform
e,
Stevens-
Johnson
syndrom
e, toxic
epiderma
l
necrolysi
s &
exfoliativ
e
dermatiti
s.
mg hrs penicillin.
b. Instruct
to take
the entire
quantity
of drug
exactly as
prescribed
even after
she feels
better.
c.
Encourage
to
increase
fluid
intake.
d. Take
the
medicatio
151
n in full
stomach.
e. Report
for any
signs of
unusualiti
es.
( Wilson,
et. al,2004
page
1415).
Drug Study
Generic
Name
Brand
Name
Classificati
on
Mechani
sm of
Action
Indication Contraindica
tion
Side Effects How
Supplie
d
Dosage/
Frequen
cy
Nursing
Interventio
n
Ipratropi
um
Duave
nt
Antiasthm
atic
Stimulat
es beta
Manageme
nt of
Hypertrophi
c
Headache,p
ain,
Pulmon
eb
1 neb
now
1. Obtain
record and
152
salbutam
ol
sulfate,
2
receptor
s on the
bronchi.
Causes
less
tachycar
dia and
is longer
acting.
(Woods,
Sratto,
28)
reversible
bronchosp
asm
associated
w/
obstructive
airway
diseases
eg
bronchial
asthma,
COPD
obstructive
cardiomyop
athy or
tachyarryth
mia.
Hypersensiti
vity to soya
lecithin or
related food
products
(for MDI).
influenza,
chest pain;
nausea.
Bronchitis,
dyspnea,
coughing,
pneumonia,
bronchospa
sm,
pharyngitis,
sinusitis,
rhinitis.
solution
2.5 mL
baseline
vital sings
2. Assess
the
presence of
palpitations
and
dysrhythmi
as
3. Perform
assessmen
t of the
patient’s
mental
status
4. Warm
patient
about
possible
paradoxical
153
bronchospa
sm
5. use
cautiously
to patients
with CV
disorders,
hypertensi
on, renal
disease
and
diabetes.
154
IVF STUDY
Student’s Name: Group 4 Section R Date of Submission: January 8, 2009
Area: Chong Hua Hospital Cliinical Instructor: Benita Edelia D.
Agramon
Patient’s Name: Patient X Doctor: Dr. R. Go
Room/Bed No.: C-414 Date of Admission: December 13, 2008
Age: 66 years old Hospital No.: 0-800-22500-773
Status: Widowed Diet: Liquid diet
155
Type of
solutio
n
Classificatio
n
Content Mechanis
m of
action
Indications Contraindicatio
ns
How
supplie
d
Dosage Nursing
Responsibiliti
es
0.9%
Sodium
chlorid
e
solutio
n
Isotonic Each 1000
mL
contains
900mg of
Sodium
Chloride
Osmolarit
y:
308
mOsm/L
Electrolyte
s in 1000
mL:
Sodium…
Replaces
sodium
and
chloride
and
maintains
levels
(Lippincot
t Williams
& Wilkins:
2005,
879).
Fluid and
electrolyte
replacement
in
hyponatrem
ia caused by
electrolyte
loss or in
severe salt
depletion.
Contraindicate
d in patients
with conditions
in which
sodium
chloride
administration
is detrimental.
>contraindicat
ed in patients
with with
increased,
normal, or only
slightly
decreased
I.V. 1
liter
IVF
PNSS 1
liter @
30
gtts/mi
n
1. Monitor
electrolyte
levels
(Lippincott
Williams &
Wilkins: 2005,
879).
2. Explain use
and
Administratio
n of drug to
patient and
family
(Lippincott
Williams &
156
154 mmol
Chloride…
154 mmol
electrolyte
levels.
Wilkins: 2005,
879).
3.Tell Patient
to report
adverse
reactions
promptly
(Lippincott
Williams &
Wilkins: 2005,
879).
4.Regulate
flow rate as
ordered
(Lippincott
Williams &
Wilkins: 2005,
879).
6.Check on
skin integrity
157
for redness,
edema,
swelling and
pain
(Lippincott
Williams &
Wilkins: 2005,
879).
7.Do not let
the bottle be
consumed
totally to
prevent air
embolism
(Lippincott
Williams &
Wilkins: 2005,
879).
8.Check mfor
any bubbles
158
present on
the I.V. line
(Lippincott
Williams &
Wilkins: 2005,
879).
Type of
solution
Classification Content Mechanism of
action
Indications Contraindication
s
How
suppli
ed
Dosage Nursing
Responsibiliti
es
Dopami
ne
Sympathomim
etic, direct
acting and
indirect acting
Syntheti
c
Dopami
ne
Dopamine is
the
immediate
precursor of
epinephrine
in the body.
Adjunct to
standard
measures
to
improve:
BP,
Pheochromocyt
oma,
uncorrected
tachycardia,
ventricular
fibrillation, or
IVF
500 ml
PB
Dopami
ne IV @
30
gtts/min
1. Dilute just
prior to
administratio
n, solution
stable for 24
hr at room
159
Exogenously
administered,
it produces
direct
stimulation of
beta-1
receptors and
variable
(dose-
dependent)
stimulation of
alpha
receptors
(peripheral
vasoconstricti
on). Will
cause a
release of
norepinephrin
e from, as its
Cardiac
output,
urine
output, in
treatment
of shock,
unrespons
ive to fluid
replaceme
nt.
arrhythmias.
Pediatric clients.
temperature,
protect from
light.
2. To prevent
fluid
overload,
may use
more
concentrated
solutions with
higher doses.
3. Administer
using an
electronic
infusion
device.
Carefully
reconstitute
and calculate
160
storage sites.
These action
results in
increased
myocardial
contraction,
CO, and SV as
well as
increased
renal blood
flow and
sodium
excretion.
Exert little
effects on
DBP and
induces fewer
dosage.
4. When
discontinuing
, gradually
decrease
dose,
sudden
cessation
may cause
marked
hypotension.
5.Monitor VS,
I&O, and
ECG; titrate
infusion to
maintain SBP
as ordered.
6. Be
prepared to
monitor CVP
161
and PAWP.
Report
ectopy,
palpitations,
anginal pain,
or
vasoconstrict
ion.
7. Explain to
the family
that drug
administered
IV to improve
cardiac
function thus
increasing BP
and
improving
urine output.
162
8. Report any
chest pain,
increase
SOB,
headaches,
or IV site
pain.
Type of
solutio
n
Classificatio
n
Content Mechanism
of action
Indication
s
Contraindicatio
ns
How
supplie
d
Dosage Nursing
Responsibiliti
es
163
D5NSS Hypertonic Each 1000
mL
contains
1000mg
of Sodium
Chloride
Osmolarit
y:
500
mOsm/L
Electrolyte
s in 1000
mL:
Sodium…
354 mmol
Chloride…
354 mmol
The solution
has a higher
sodium
concentratio
n than to
the
intracellular
area thus by
virtue of
osmosis the
water is
taken out of
the cell the
cell shrinks.
This
increases
the plasma
volume of
the blood.
Rehydrat
e; has
free
water,
salt and
calories
Contraindicate
d in patients
with conditions
in which
sodium
chloride
administration
is detrimental.
>contraindicat
ed in patients
with with
increased,
normal, or only
slightly
decreased
electrolyte
levels.
I.V. 1
liter
IVF
D5NSS
1 liter
@ 30
gtts/mi
n
1. Monitor
electrolyte
levels
(Lippincott
Williams &
Wilkins: 2005,
879).
2. Explain use
and
Administratio
n of drug to
patient and
family
(Lippincott
Williams &
Wilkins: 2005,
879).
3.Tell Patient
to report
adverse
164
reactions
promptly
(Lippincott
Williams &
Wilkins: 2005,
879).
4.Regulate
flow rate as
ordered
(Lippincott
Williams &
Wilkins: 2005,
879).
6.Check on
skin integrity
for redness,
edema,
swelling and
pain
165
(Lippincott
166
top related